Agile Therapeutics (AGRX) Received its Third Buy in a Row

By Jason Carr

After Oppenheimer and H.C. Wainwright gave Agile Therapeutics (NASDAQ: AGRX) a Buy rating last month, the company received another Buy, this time from Maxim Group. Analyst Jason McCarthy reiterated a Buy rating on Agile Therapeutics yesterday and set a price target of $8.00. The company’s shares closed last Tuesday at $3.11.

According to, McCarthy is a 5-star analyst with an average return of 29.3% and a 48.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.

Agile Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $8.67, implying a 154.3% upside from current levels. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $12.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.77 and a one-year low of $0.35. Currently, Agile Therapeutics has an average volume of 1.55M.

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGRX in relation to earlier this year. Last month, Alfred Altomari, the CEO of AGRX bought 94,599 shares for a total of $166,494.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.